AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Trading 04-30 11:47:52 EDT

3.84

+0.00

-0.13%

High4.00	Low3.73	Vol395.53K
Open3.82	D1 Closing3.84	Amplitude7.16%
Mkt Cap1.12B	Tradable Cap735.39M	Total Shares292.78M
T/O1.54M	T/O Rate0.21%	Tradable Shares191.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":3.835,"timestamp":1714492048413,"preClose":3.84,"halted":0,"volume":395530,"delay":0,"floatShares":191758285,"shares":292782152,"eps":-0.51,"marketStatus":"Trading","change":-0.005,"latestTime":"04-30 11:47:52 EDT","open":3.82,"high":4,"low":3.725,"amount":1537635.057324,"amplitude":0.071615,"askPrice":3.84,"askSize":1211,"bidPrice":3.83,"bidSize":605,"shortable":3,"etf":0,"ttmEps":-0.51,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1714507200000},"marketStatusCode":2,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":3.84,"preHourTrading":{"tag":"盘前","latestPrice":3.8926,"preClose":3.84,"latestTime":"09:29 EDT","volume":122,"amount":473.53619239999995,"timestamp":1714483759732},"postHourTrading":{"tag":"盘后","latestPrice":3.8,"preClose":3.84,"latestTime":"19:50 EDT","volume":5612,"amount":21518.9188,"timestamp":1714434658710},"volumeRatio":0.71471},"requestUrl":"/m/hq/s/ABCL","defaultTab":"news","newsList":[{"id":"2426605943","title":"AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2426605943","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2426605943?lang=en_us&edition=fundamental","pubTime":"2024-04-09 00:05","pubTimestamp":1712592300,"startTime":"0","endTime":"0","summary":"Data show how AbCellera is expanding the reach of T-cell engagers with:. CD3-binding antibodies that consistently generate T-cell engagers with potent tumor-cell killing and low cytokine release across multiple tumor targets, including PSMA, B7-H4, and 5T4. Costimulatory CD28-binding antibodies that stimulate T cells without superagonist activity. Highly specific T-cell engagers for the peptide-MHC target MAGE-A4. AbCellera’s poster presentations, which are available for viewing here, describe how AbCellera is:. Widening the therapeutic window: AbCellera’s data describe the generation of TCEs for three solid tumor targets, PSMA, B7-H4, and 5T4, with functional profiles that are differentiated from clinical benchmarks. These molecules were engineered using a specific set of rare CD3-binding antibodies that consistently show potent tumor-cell killing and low cytokine release across multiple targets, demonstrating their potential to expand the therapeutic window across solid tumor indicat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/okBKIcp13raUMZa5Fx5CQw--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/59abd10f84a78517f61733b091206a34","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/okBKIcp13raUMZa5Fx5CQw--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/59abd10f84a78517f61733b091206a34"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-presents-data-t-cell-160500959.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424874705","title":"Press Release: AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2424874705","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2424874705?lang=en_us&edition=fundamental","pubTime":"2024-04-04 04:07","pubTimestamp":1712174820,"startTime":"0","endTime":"0","summary":"AbCellera  will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time  the same day.A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call.AbCellera  discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2422926957","title":"The 7 Best Penny Stocks to Buy in Q2 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2422926957","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2422926957?lang=en_us&edition=fundamental","pubTime":"2024-03-28 04:30","pubTimestamp":1711571400,"startTime":"0","endTime":"0","summary":"Taboola : Exceeded Q4 earnings with optimistic 2024 growth.Adaptive Biotechnologies : MRD revenue growth positions it for a rebound.Grab Holdings : Expanding digital banking and AI investments for profitability.Keep reading for more penny stocks to buy ideas!This month in March is a great time to pick up shares in these best penny stocks to buy. I chose the companies due to their strong fundamentals and potential for significant upside. Investing in penny stocks can provide the opportunity for substantial returns, as these lower-priced shares have more room for capital appreciation compared to large-cap stocks.The company concluded 2023 with solid fourth-quarter earnings and is optimistic about its growth in 2024. In Q4 2023, revenue grew by 13% year-over-year to $419.8 million, and the Adjusted EBITDA was $50.1 million, exceeding their guidance.Taboola’s strategic focus includes leveraging its partnership with Yahoo, which is expected to contribute over $100 million in Q1 2024. The co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/03/the-7-best-penny-stocks-to-buy-in-q2-2024/","is_publish_highlight":false,"gpt_icon":0},{"id":"2422678573","title":"Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2422678573","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2422678573?lang=en_us&edition=fundamental","pubTime":"2024-03-27 05:25","pubTimestamp":1711488308,"startTime":"0","endTime":"0","summary":"In this article, we will take a detailed look atBillionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks.For a quick overview of such stocks, read our articleBillionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 5 Stocks.Druckenmiller isn’t a huge fan of portfolio diversification. He said during the interview that if you really believe in a company, you’d take “massive” positions in it instead of putting your money in hundreds of companies. He said legendary investors like Warren Buffett, Carl Icahn and George Soros invest in a handful of companies they really like and believe in. Druckenmiller said instead of having “lazy longs” in your portfolio, if you put your money in just a few companies, you won’t get careless in the investing game.Canadian biotechnology company Abcellera Biologics Inc.  ranks 11th in our list of the stocks billionaire Stanley Druckenmiller and insiders are buying. John Montalbano, a director at Abcellera Biologic","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EBUwHCTiF7appzBhbShGkg--~B/aD03NjA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3ad4fdbcd56f71ef3267a321671c1689","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EBUwHCTiF7appzBhbShGkg--~B/aD03NjA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3ad4fdbcd56f71ef3267a321671c1689"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/billionaire-investor-stan-druckenmiller-insiders-212508357.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2418360994","title":"AbCellera gains on antibody collaboration with Biogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2418360994","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2418360994?lang=en_us&edition=fundamental","pubTime":"2024-03-12 00:23","pubTimestamp":1710174200,"startTime":"0","endTime":"0","summary":"AbCellera Biologics  is up ~3% in Monday trading after announcing a collaboration with Biogen  to develop antibodies to treat neurological ailments. The agreement calls for the discovery of a novel target that would allow for the delivery of treatment through the blood brain barrier.   Terms call for AbCellera  to receive an undisclosed upfront payment as well as milestone payments. The company is also eligible to receive royalties on sales of therapies developed through the collaboration that make it to market.   More on AbCellera, Biogen  Biogen Inc.  TD Cowen 44th Annual Health Care Conference -  AbCellera: Victim Of Its Own Success AbCellera Biologics Inc.  Q4 2023 Earnings Call Transcript Biogen Alzheimer’s drug off to a slower rollout in U.S., partner Eisai says Peter Thiel resigns from AbCellera board for personal reasons","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1441786721/image_1441786721.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1441786721/image_1441786721.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4078071-abcellera-gains-antibody-collaboration-biogen","is_publish_highlight":false,"gpt_icon":0},{"id":"2418366251","title":"Deals of the day-Mergers and acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2418366251","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2418366251?lang=en_us&edition=fundamental","pubTime":"2024-03-11 22:42","pubTimestamp":1710168121,"startTime":"0","endTime":"0","summary":"(Adds: IndiGo Astorg, TenneT, Aditya Birla Capital Ltd, Daily Telegraph , Choice Hotels International, Fortrea Holdings, EQT Corp)      March 11 (Reuters) - The following bids, mergers, acquisitions a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2418357972","title":"BRIEF-Abcellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2418357972","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2418357972?lang=en_us&edition=fundamental","pubTime":"2024-03-11 21:24","pubTimestamp":1710163458,"startTime":"0","endTime":"0","summary":"March 11 (Reuters) - Abcellera Biologics Inc   :   * ABCELLERA TO COLLABORATE WITH BIOGEN TO DISCOVER THERAPEUTIC ANTIBODIES FOR NEUROLOGICAL CONDITIONS   * ABCELLERA BIOLOGICS - WILL RECEIVE UPFRONT ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2418352127","title":"AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2418352127","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2418352127?lang=en_us&edition=fundamental","pubTime":"2024-03-11 21:00","pubTimestamp":1710162000,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, March 11, 2024----AbCellera  and Biogen Inc.  have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.\"Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,\" said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera. \"We are excited to work with Biogen on this innovative program, which has the potential to unlock multiple new approaches to treating neurological conditions.\". Under the terms of the agreement, AbCellera will receive an upfront payment and is eligible to receive additional milestone payments should the research programs achieve certain research, developmental and regulatory milestones. AbCellera is also eligible to receive potential royalties on future net sales of products that result from the collaboration.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mGYYO1AQ5Oe4DvU6G0..mA--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/81f5b17629e2025f06ac27c2c4fa296d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mGYYO1AQ5Oe4DvU6G0..mA--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/81f5b17629e2025f06ac27c2c4fa296d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-collaborate-biogen-discover-therapeutic-130000478.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417473582","title":"AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2417473582","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2417473582?lang=en_us&edition=fundamental","pubTime":"2024-03-06 05:30","pubTimestamp":1709674200,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, March 05, 2024----AbCellera  today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research  Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center.With its T-cell engager platform, AbCellera is expanding therapeutic opportunities for this modality by generating molecules with the potential for improved efficacy and safety profiles for solid tumors and challenging targets such as peptide-MHCs.Title: Functional and specific T-cell engagers against a peptide-MHC tumor targetAbstract Number: 2373Session: Antibodies 1Date and Time: Monday, April 8, 2024, 9:00 a.m. to 12:30 p.m. PTLocation: Section 38, Board 19. Title: Target-dependent considerations for the design of bispecific T-cell engagersAbstract Number: 1868Session: Antibody-Based Technologies and New InhibitorsDate and Time: Monday, April 8, 2024, 9:00 a.m. to 12:30 p.m. PTLoca","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rWrb.AaAXAJWDTDDJ6nyaQ--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/08a27b3d41b8b9b69934145e6b9fbf29","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rWrb.AaAXAJWDTDDJ6nyaQ--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/08a27b3d41b8b9b69934145e6b9fbf29"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-announces-four-presentations-t-213000693.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2415545140","title":"After losing 38% in the past year, AbCellera Biologics Inc. (NASDAQ:ABCL) institutional owners must be relieved by the recent gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2415545140","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2415545140?lang=en_us&edition=fundamental","pubTime":"2024-02-29 19:27","pubTimestamp":1709206033,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in AbCellera Biologics implies that they have significant influence over the company's share price. A total of 8 investors have a majority stake in the company with 51% ownership. To get a sense of who is truly in control of AbCellera Biologics Inc. , it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are institutions with 36% ownership. Put another way, the group faces the maximum upside potential .Institutional investors would appreciate the 5.6% increase in share price last week, given their one-year losses have totalled a disappointing 38%.In the chart below, we zoom in on the different ownership groups of AbCellera Biologics.Check out our latest analysis for AbCellera Biologics. NasdaqGS:ABCL Earnings and Revenue Growth February 29th 2024. The definition of an insider can differ slightly between different countries, but membe","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/losing-38-past-abcellera-biologics-112713341.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2414088870","title":"3 Highly Rated Biotech Stocks to Buy for 300% Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2414088870","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2414088870?lang=en_us&edition=fundamental","pubTime":"2024-02-26 19:55","pubTimestamp":1708948500,"startTime":"0","endTime":"0","summary":"Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/02/3-highly-rated-biotech-stocks-to-buy-for-300-gains/","is_publish_highlight":false,"gpt_icon":0},{"id":"2413971097","title":"BRIEF-AbCellera Announces Resignation Of Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2413971097","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2413971097?lang=en_us&edition=fundamental","pubTime":"2024-02-24 06:53","pubTimestamp":1708728788,"startTime":"0","endTime":"0","summary":"Feb 23  - Abcellera Biologics Inc   :   * ABCELLERA ANNOUNCES RESIGNATION OF BOARD MEMBER   * ABCELLERA BIOLOGICS INC - PETER THIEL HAS NOTIFIED COMPANY OF HIS INTENTION TO RESIGN FROM COMPANY'S BOARD OF DIRECTORS   * ABCELLERA BIOLOGICS INC - EFFECTIVE UPON THIEL'S RESIGNATION, SIZE OF BOARD WILL BE REDUCED FROM SIX TO FIVE DIRECTORSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413710805","title":"Peter Thiel resigns from AbCellera board for personal reasons","url":"https://stock-news.laohu8.com/highlight/detail?id=2413710805","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2413710805?lang=en_us&edition=fundamental","pubTime":"2024-02-24 06:38","pubTimestamp":1708727911,"startTime":"0","endTime":"0","summary":"AbCellera  said Peter Thiel plans to resign from its board of directors for personal reasons, effective March 7. Thiel did not inform the company that he had any disagreements with its operations, policies or practices. His resignation will reduce the number of directors on AbCellera’s board to five. A director since November 2020, Thiel also served as chairman of AbCellera’s nominating and corporate governance committee. Director Andrew Lo will assume Thiel’s spot on the committee, according to the company.  More on AbCellera Biologics  AbCellera Biologics Inc.  Q4 2023 Earnings Call Transcript AbCellera Biologics: Continuing To Expand Partnerships AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 AbCellera Biologics GAAP EPS of -$0.51 misses by $0.04, revenue of $38M misses by $0.13M Absci hits new 52-week high as race for AI drug discovery heats up","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4071356-peter-thiel-resigns-from-abcellera-board-for-personal-reasons","is_publish_highlight":false,"gpt_icon":0},{"id":"2413371229","title":"AbCellera Announces Resignation of Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2413371229","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2413371229?lang=en_us&edition=fundamental","pubTime":"2024-02-24 05:30","pubTimestamp":1708723800,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, February 23, 2024----AbCellera  today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effective March 7, 2024.\"AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field,\" said Peter Thiel. \"I am proud to have helped them with their mission.\". Mr. Thiel joined AbCellera’s Board of Directors in November 2020 and served as the Chairman of the Company’s Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company’s Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Directors.\"On behalf of the members of our board and management, I express our deep appreciation for Peter’s contributions,\" said Carl Hansen, Ph.D., founder and CEO of AbCellera. \"I would also like to personally thank Peter for his mentorship over the past three years. ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AmUc98ePcUfYbTXQrhHlTA--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4f76ff571b8b5b41432e7d9de4513a06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AmUc98ePcUfYbTXQrhHlTA--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4f76ff571b8b5b41432e7d9de4513a06"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-announces-resignation-board-member-213000672.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2413206759","title":"AbCellera to Present at Upcoming Investor Conferences in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2413206759","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2413206759?lang=en_us&edition=fundamental","pubTime":"2024-02-23 09:15","pubTimestamp":1708650900,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, February 23, 2024----AbCellera  today announced that executives from the Company will present at the following investor conferences:. 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time . KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time . Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations.About AbCellera Biologics Inc.AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/L5BAsZYReS5Q4OLUWGhGBQ--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fca94f3f0dc395b06db0e97131e7ee04","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/L5BAsZYReS5Q4OLUWGhGBQ--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fca94f3f0dc395b06db0e97131e7ee04"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-present-upcoming-investor-conferences-011500774.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2413222349","title":"Obesity drugs to expand U.S. GDP by 1% in the coming years: Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2413222349","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2413222349?lang=en_us&edition=fundamental","pubTime":"2024-02-23 03:41","pubTimestamp":1708630894,"startTime":"0","endTime":"0","summary":"The popular GLP-1 class of weight loss drugs could help boost the U.S. gross domestic product by 1% in the coming years as lower obesity rates fuel efficiency gains, Goldman Sachs said in a research n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4070545-obesity-drugs-expand-us-gdp-goldman-sachs","is_publish_highlight":false,"gpt_icon":0},{"id":"2413664297","title":"AbCellera Biologics Raised to Buy From Hold by Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2413664297","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2413664297?lang=en_us&edition=fundamental","pubTime":"2024-02-22 20:15","pubTimestamp":1708604100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABCL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 22, 2024 07:15 ET (12:15 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2413253777","title":"AbCellera Biologics: A Strong Buy on Robust Pipeline and Solid Financial Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2413253777","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2413253777?lang=en_us&edition=fundamental","pubTime":"2024-02-22 13:16","pubTimestamp":1708578971,"startTime":"0","endTime":"0","summary":"Puneet Souda, an analyst from Leerink Partners, reiterated the Buy rating on AbCellera Biologics (ABCL – Research Report). The associated price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/abcellera-biologics-a-strong-buy-on-robust-pipeline-and-solid-financial-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/abcellera-biologics-a-strong-buy-on-robust-pipeline-and-solid-financial-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2413428277","title":"Stifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2413428277","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2413428277?lang=en_us&edition=fundamental","pubTime":"2024-02-21 21:14","pubTimestamp":1708521242,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on AbCellera Biologics (ABCL – Research Report) today and set a price target of $17....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-abcellera-biologics-abcl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-abcellera-biologics-abcl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2413440941","title":"Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Teladoc (TDOC) and Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2413440941","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2413440941?lang=en_us&edition=fundamental","pubTime":"2024-02-21 20:31","pubTimestamp":1708518663,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbCellera Biologics (ABCL – Research Report), Telado...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abcellera-biologics-abcl-teladoc-tdoc-and-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abcellera-biologics-abcl-teladoc-tdoc-and-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":-0.0424},{"period":"1month","weight":-0.1523},{"period":"3month","weight":-0.2727},{"period":"6month","weight":-0.068},{"period":"1year","weight":-0.4336},{"period":"ytd","weight":-0.3275}],"compareEarnings":[{"period":"1week","weight":0.0207},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0391},{"period":"6month","weight":0.2068},{"period":"1year","weight":0.2263},{"period":"ytd","weight":0.0731}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.031012},{"month":2,"riseRate":0,"avgChangeRate":-0.132842},{"month":3,"riseRate":0.25,"avgChangeRate":-0.046348},{"month":4,"riseRate":0,"avgChangeRate":-0.170425},{"month":5,"riseRate":0.666667,"avgChangeRate":0.00942},{"month":6,"riseRate":0.333333,"avgChangeRate":0.048148},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.057046},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.041693},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.011885},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.042144},{"month":11,"riseRate":0.666667,"avgChangeRate":0.062052},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.014901}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction